Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peginterferon α-2a plus ribavirin in Latino and Non-Latino Whites with HCV genotype 1: Histologic outcomes and tolerability from the LATINO Study.

The American journal of gastroenterology - 1 Oct 2010

Balart Luis A, Lisker-Melman Mauricio, Hamzeh Fayez M, Kwok Ambrose, Lentz Ellen, Rodriguez-Torres Maribel

Abstract excerpt

OBJECTIVES: We sought to compare the histologic response, safety, and tolerability in Latino and non-Latino patients with hepatitis C virus (HCV) genotype 1 treated with peginterferon α-2a plus ribavirin (LATINO study). METHODS: LATINO was a prospective, open-label, multicenter study that enrolle...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Hepatitis C
Share to Hispanic or Latino

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Liver Cirrhosis

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 20389293
DOI: 10.1038/ajg.2010.157

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-20389293-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peginterferon α-2a plus ribavirin in Latino and Non-Latino Whites with HCV genotype 1: Histologic outcomes and tolerability from the LATINO Study.PMID 20389293Read ↗

Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.Semantic proximity Read ↗

A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.Semantic proximity Read ↗

The epidemiologic burden of hepatitis C virus infection in Latin America .Semantic proximity Read ↗

HEPLA: A multicenter study on demographic and disease characteristics of patients with hepatitis C in Latin America.Semantic proximity Read ↗

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.Semantic proximity Read ↗

Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.Semantic proximity Read ↗

The impact of ethnicity on hepatitis C virus treatment decisions and outcomes.Semantic proximity Read ↗

Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites.Semantic proximity Read ↗

Elevated serum α-fetoprotein levels in patients with chronic hepatitis C virus genotype 4: not the end of the story.Semantic proximity Read ↗

Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks.Semantic proximity Read ↗

Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic.Semantic proximity Read ↗

Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.